Amneal Pharmaceuticals, Inc. (2DT.F)

3,9130 -0,0130 (-0,33%) Ab 9:16AM MEZ. Markt geöffnet.

Amneal Pharmaceuticals, Inc.

400 Crossing Boulevard
3rd Floor
Bridgewater, NJ 08807
United States
908 947 3120
http://www.amneal.com

Sektor(en): Healthcare
Branche: Drug Manufacturers—Specialty & Generic
Vollzeitmitarbeiter: 5.500

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Chirag K. Patel	Co-Founder, Co-CEO, Pres & Director	62,97k	N/A	1967
Mr. Chintu Patel R.Ph., R.Ph	Co-Founder, Co-CEO & Director	64,6k	N/A	1972
Mr. Andrew S. Boyer	Exec. VP & Chief Commercial Officer of Generics	675,09k	N/A	1966
Mr. Anastasios G. Konidaris	Exec. VP & CFO	N/A	N/A	1967
Mr. Stephen J. Manzano	Sr. VP, Gen. Counsel & Corp. Sec.	N/A	N/A	1965
Mr. James Luce	Exec. VP of Sales & Marketing	N/A	N/A	N/A
Ms. Nikita Shah	Exec. VP and Chief HR Officer & Strategic Planning Officer	N/A	N/A	1978
Mr. Sanjiv Patel	Sr. VP of Operations	N/A	N/A	N/A
Ms. Candis Edwards	Sr. VP of Regulatory Affairs	N/A	N/A	N/A
Mr. Joseph Todisco MBA	Exec. VP & Chief Commercial Officer of Specialty	N/A	N/A	1976

Die Beträge haben den Stand 31. Dezember 2019 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It has operations in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.

Corporate Governance

Amneal Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Dezember 2020, lautet 6. Die grundlegenden Scores sind Audit: 2, Vorstand: 9, Shareholderrechte: 4, Kompensation: 3.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.